Literature DB >> 35925484

Chitosan reduces inflammation and protects against oxidative stress in a hyperlipidemic rat model: relevance to nonalcoholic fatty liver disease.

Raushan Kumar1, Jitendra Kumar Arya1, Syed Ibrahim Rizvi2.   

Abstract

BACKGROUND: An altered lipid profile may lead to the development of inflammation and NAFLD (Non-alcoholic fatty liver disease). Although statins have a positive effect on blood lipid levels their long-term use is known to cause adverse effects, in this backdrop there is an interest in natural compounds which may affect lipid metabolism and prevent NAFLD. We have examined the effect of Chitosan on rats subjected to a high-fat diet. METHODS AND
RESULTS: Male Wistar middle aged rats (12-16 months) were treated with high-fat diet orally for two months for creating a NAFLD model. Rats were also supplemented with Chitosan (2% chitosan daily) for 2 months. We assessed the activity of antioxidant enzymes, the histopathological profile of the liver. Inflammatory cytokines and adiponectin levels were also measured in serum. HFD induced significant changes in liver tissue and inflammatory markers (Il-6, TNF- alpha, NF-KB). Chitosan treatment protected rats from HFD induced alterations.
CONCLUSIONS: The findings suggest that Chitosan can effectively improve liver lipid metabolism by normalizing cholesterol, triglyceride, lowering NF-KB expression, and protecting the liver from oxidative stress by improving hepatic function. Chitosan also regulates genes related to lipidemic stress i,e leptin and adiponectin.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Chitosan; High-fat diet; Liver; Non-alcoholic fatty liver disease; Oxidative stress

Mesh:

Substances:

Year:  2022        PMID: 35925484     DOI: 10.1007/s11033-022-07810-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.742


  36 in total

Review 1.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

Review 2.  New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.

Authors:  Natalia Pydyn; Katarzyna Miękus; Jolanta Jura; Jerzy Kotlinowski
Journal:  Pharmacol Rep       Date:  2020-01-08       Impact factor: 3.024

Review 3.  Statin Toxicity.

Authors:  Natalie C Ward; Gerald F Watts; Robert H Eckel
Journal:  Circ Res       Date:  2019-01-18       Impact factor: 17.367

Review 4.  N-acetylglucosamine: production and applications.

Authors:  Jeen-Kuan Chen; Chia-Rui Shen; Chao-Lin Liu
Journal:  Mar Drugs       Date:  2010-09-15       Impact factor: 5.118

Review 5.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

Review 6.  Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications.

Authors:  Elisa Fabbrini; Shelby Sullivan; Samuel Klein
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

Review 7.  Unfolding the pleiotropic facades of rosuvastatin in therapeutic intervention of myriads of neurodegenerative disorders.

Authors:  Ibraheem Husain; Sana Khan; Saba Khan; Tushar Madaan; Sanjeev Kumar; Abul K Najmi
Journal:  Clin Exp Pharmacol Physiol       Date:  2018-10-05       Impact factor: 2.557

Review 8.  Non-alcoholic fatty liver disease: An expanded review.

Authors:  Mark Benedict; Xuchen Zhang
Journal:  World J Hepatol       Date:  2017-06-08

Review 9.  Herbal drug discovery for the treatment of nonalcoholic fatty liver disease.

Authors:  Tingting Yan; Nana Yan; Ping Wang; Yangliu Xia; Haiping Hao; Guangji Wang; Frank J Gonzalez
Journal:  Acta Pharm Sin B       Date:  2019-12-10       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.